TY - JOUR
T1 - Toll-like receptors in acute kidney injury
AU - Vázquez-Carballo, Cristina
AU - Guerrero-Hue, Melania
AU - García-Caballero, Cristina
AU - Rayego-Mateos, Sandra
AU - Opazo-Ríos, Lucas
AU - Morgado-Pascual, José Luis
AU - Herencia-Bellido, Carmen
AU - Vallejo-Mudarra, Mercedes
AU - Cortegano, Isabel
AU - Gaspar, María Luisa
AU - De Andrés, Belén
AU - Egido, Jesús
AU - Moreno, Juan Antonio
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/1/2
Y1 - 2021/1/2
N2 - Acute kidney injury (AKI) is an important health problem, affecting 13.3 million individuals/ year. It is associated with increased mortality, mainly in low- and middle-income countries, where renal replacement therapy is limited. Moreover, survivors show adverse long-term outcomes, including increased risk of developing recurrent AKI bouts, cardiovascular events, and chronic kidney disease. However, there are no specific treatments to decrease the adverse consequences of AKI. Epidemiological and preclinical studies show the pathological role of inflammation in AKI, not only at the acute phase but also in the progression to chronic kidney disease. Toll-like receptors (TLRs) are key regulators of the inflammatory response and have been associated to many cellular processes activated during AKI. For that reason, a number of anti-inflammatory agents targeting TLRs have been analyzed in preclinical studies to decrease renal damage during AKI. In this review, we updated recent knowledge about the role of TLRs, mainly TLR4, in the initiation and development of AKI as well as novel compounds targeting these molecules to diminish kidney injury associated to this pathological condition.
AB - Acute kidney injury (AKI) is an important health problem, affecting 13.3 million individuals/ year. It is associated with increased mortality, mainly in low- and middle-income countries, where renal replacement therapy is limited. Moreover, survivors show adverse long-term outcomes, including increased risk of developing recurrent AKI bouts, cardiovascular events, and chronic kidney disease. However, there are no specific treatments to decrease the adverse consequences of AKI. Epidemiological and preclinical studies show the pathological role of inflammation in AKI, not only at the acute phase but also in the progression to chronic kidney disease. Toll-like receptors (TLRs) are key regulators of the inflammatory response and have been associated to many cellular processes activated during AKI. For that reason, a number of anti-inflammatory agents targeting TLRs have been analyzed in preclinical studies to decrease renal damage during AKI. In this review, we updated recent knowledge about the role of TLRs, mainly TLR4, in the initiation and development of AKI as well as novel compounds targeting these molecules to diminish kidney injury associated to this pathological condition.
KW - Acute kidney injury
KW - Drugs
KW - Inflammation
KW - Therapy
KW - Toll-like receptors
UR - http://www.scopus.com/inward/record.url?scp=85099579011&partnerID=8YFLogxK
U2 - 10.3390/ijms22020816
DO - 10.3390/ijms22020816
M3 - Article
C2 - 33467524
AN - SCOPUS:85099579011
SN - 1661-6596
VL - 22
SP - 1
EP - 27
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 2
M1 - 816
ER -
